{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:34:00Z","timestamp":1789760040780,"version":"4.0.1"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T00:00:00Z","timestamp":1518652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P30ES013508"],"award-info":[{"award-number":["P30ES013508"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002108","name":"Friedreich's Ataxia Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5UL1TR001878"],"award-info":[{"award-number":["5UL1TR001878"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R03HD092630"],"award-info":[{"award-number":["R03HD092630"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0192779","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T13:48:10Z","timestamp":1518702490000},"page":"e0192779","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Low apolipoprotein A-I levels in Friedreich\u2019s ataxia and in frataxin-deficient cells: Implications for therapy"],"prefix":"10.1371","volume":"13","author":[{"given":"QingQing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra J.","family":"Strawser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel W.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementina","family":"Mesaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0366-8658","authenticated-orcid":true,"given":"Ian A.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,2,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","article-title":"Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes","volume":"6","author":"V Campuzano","year":"1997","journal-title":"Hum Mol Genet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng0897-345","article-title":"Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin","volume":"16","author":"H Koutnikova","year":"1997","journal-title":"Nat Genet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-2008-1040847","article-title":"Friedreich's ataxia: clinical aspects and pathogenesis","volume":"19","author":"M Pandolfo","year":"1999","journal-title":"Semin Neurol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1093\/hmg\/ddh324","article-title":"Iron-sulfur protein maturation in human cells: evidence for a function of frataxin","volume":"13","author":"O Stehling","year":"2004","journal-title":"Hum Mol Genet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1474-4422(14)70321-7","article-title":"Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data","volume":"14","author":"K Reetz","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehq443","article-title":"Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome","volume":"32","author":"SV Raman","year":"2011","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0883073812448535","article-title":"Cardiomyopathy in Friedreich ataxia: clinical findings and research","volume":"27","author":"RM Payne","year":"2012","journal-title":"J Child Neurol"},{"issue":"Suppl 1","key":"ref8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jnc.12217","article-title":"Cardiomyopathy of Friedreich ataxia","volume":"126","author":"F Weidemann","year":"2013","journal-title":"J Neurochem"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e0116396","DOI":"10.1371\/journal.pone.0116396","article-title":"The pathogenesis of cardiomyopathy in Friedreich ataxia","volume":"10","author":"AH Koeppen","year":"2015","journal-title":"PLoS ONE"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00246-008-9305-1","article-title":"The longitudinal course of cardiomyopathy in Friedreich's ataxia during childhood","volume":"30","author":"A Kipps","year":"2009","journal-title":"Pediatr Cardiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/mds.22864","article-title":"Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia","volume":"25","author":"B Rajagopalan","year":"2010","journal-title":"Mov Disord"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/14734220600913246","article-title":"Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia","volume":"5","author":"S Michael","year":"2006","journal-title":"Cerebellum"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/hmg\/ddr554","article-title":"A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model","volume":"21","author":"PM Vyas","year":"2012","journal-title":"Hum Mol Genet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"GD Lopaschuk","year":"2010","journal-title":"Physiol Rev"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1042\/BST20140094","article-title":"Role of CoA and acetyl-CoA in regulating cardiac fatty acid and glucose oxidation","volume":"42","author":"O Abo Alrob","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/bph.12475","article-title":"Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy","volume":"171","author":"N Fillmore","year":"2014","journal-title":"Brit J. Pharmacol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/84818","article-title":"Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits","volume":"27","author":"H Puccio","year":"2001","journal-title":"Nat Genet"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.16043","article-title":"Loss of Frataxin induces iron toxicity, sphingolipid synthesis, and Pdk1\/Mef2 activation, leading to neurodegeneration","volume":"5","author":"K Chen","year":"2016","journal-title":"Elife"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.20732","article-title":"Loss of Frataxin activates the iron\/sphingolipid\/PDK1\/Mef2 pathway in mammals","volume":"5","author":"K Chen","year":"2016","journal-title":"Elife"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1590\/S0100-879X2009000500004","article-title":"Association of HDL cholesterol and triglycerides with mortality in patients with heart failure","volume":"42","author":"HFG Freitas","year":"2009","journal-title":"Braz J Med Biol Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/187153012800493521","article-title":"Cardiac effects of HDL and its components on diabetic cardiomyopathy","volume":"12","author":"F Spillmann","year":"2012","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s11845-012-0808-7","article-title":"Cardiomyopathy of Friedreich's ataxia (FRDA)","volume":"181","author":"RM Payne","year":"2012","journal-title":"Ir J Med Sci"},{"key":"ref23","first-page":"382","article-title":"Plasma lipoprotein concentration and erythrocyte membrane lipids in patients with Friedreich's ataxia","volume":"2","author":"A Filla","year":"1980","journal-title":"Acta Neurol (Napoli)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/jnnp.43.2.111","article-title":"Lipids and lipoproteins in Friedreich's ataxia","volume":"43","author":"JL Walker","year":"1980","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000117329","article-title":"Serum lipids, lipoprotein analysis and apoprotein A-I, A-II and B levels in Friedreich's ataxia","volume":"30","author":"G Baldo-Enzi","year":"1990","journal-title":"Eur Neurol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1002\/art.27546","article-title":"Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis","volume":"62","author":"N Vuilleumier","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/labinvest.2016.56","article-title":"ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease","volume":"96","author":"DA Chistiakov","year":"2016","journal-title":"Lab Invest"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.4155\/bio.15.195","article-title":"Serum apolipoprotein A-1 quantification by LC-MS with a SILAC internal standard reveals reduced levels in smokers","volume":"7","author":"Q Wang","year":"2015","journal-title":"Bioanalysis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1194\/jlr.P002816","article-title":"Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database","volume":"51","author":"PJ Barter","year":"2010","journal-title":"J Lipid Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.hlc.2014.04.007","article-title":"Statin therapy improves long-term survival in non-ischaemic cardiomyopathy: a pooled analysis of 4500 patients","volume":"23","author":"SV Deo","year":"2014","journal-title":"Heart Lung Circ"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/1755-5922.12150","article-title":"Effects of Statin Treatment on Inflammation and Cardiac Function in Heart Failure: An Adjusted Indirect Comparison Meta-Analysis of Randomized Trials","volume":"33","author":"KO Bonsu","year":"2015","journal-title":"Cardiovasc Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/rcm.7667","article-title":"Diisopropylethylamine\/hexafluoroisopropanol-mediated ion-pairing ultra-high-performance liquid chromatography\/mass spectrometry for phosphate and carboxylate metabolite analysis: utility for studying cellular metabolism","volume":"30","author":"L Guo","year":"2016","journal-title":"Rapid Commun Mass Spectrom"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.bbalip.2011.01.002","article-title":"Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS\/MS","volume":"1811","author":"L Henneman","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/14737175.2017.1356721","article-title":"Pharmacological therapeutics in Friedreich Ataxia: The present state","volume":"17","author":"C Strawser","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12014-016-9121-1","article-title":"Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease","volume":"13","author":"C Mesaros","year":"2016","journal-title":"Clin Proteomics"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.114.001885","article-title":"Risk of Heart Failure and Death After Prolonged Smoking Cessation: Role of Amount and Duration of Prior Smoking","volume":"8","author":"AA Ahmed","year":"2015","journal-title":"Circ Heart Fail"},{"key":"ref37","first-page":"1683","article-title":"Smoking cessation in heart failure: it is never too late","volume":"37","author":"J Lightwood","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0091-7435(03)00110-5","article-title":"The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis","volume":"37","author":"K Maeda","year":"2003","journal-title":"Prev Med"},{"key":"ref39","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/612089","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"2010","author":"M Rakhshandehroo","year":"2010","journal-title":"PPAR Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.numecd.2007.05.001","article-title":"Increasing apoA-I production as a target for CHD risk reduction","volume":"17","author":"SPJ Dullens","year":"2007","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1172\/JCI10852","article-title":"Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I","volume":"107","author":"G Martin","year":"2001","journal-title":"J Clin Invest"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0021-9150(01)00754-7","article-title":"Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes","volume":"163","author":"V Bonn","year":"2002","journal-title":"Atherosclerosis"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.bbrc.2004.09.122","article-title":"Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell","volume":"324","author":"T Maejima","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/hmg\/ddm102","article-title":"In vivo maturation of human frataxin","volume":"16","author":"I Condo","year":"2007","journal-title":"Hum Mol Genet"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/hmg\/ddn244","article-title":"The in vivo mitochondrial two-step maturation of human frataxin","volume":"17","author":"S Schmucker","year":"2008","journal-title":"Hum Mol Genet"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e63958","DOI":"10.1371\/journal.pone.0063958","article-title":"Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia","volume":"8","author":"HL Plasterer","year":"2013","journal-title":"PLoS ONE"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/01.CIR.104.3.317","article-title":"Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy","volume":"104","author":"R Patel","year":"2001","journal-title":"Circulation"},{"key":"ref48","article-title":"Liquid chromatography-high resolution mass spectrometry analysis of platelet frataxin as a protein biomarker for the rare disease Friedreich's Ataxia","author":"L Guo","year":"2017","journal-title":"Anal Chem"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0192779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T10:47:44Z","timestamp":1540032464000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0192779"}},"subtitle":[],"editor":[{"given":"Stephan N.","family":"Witt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,2,15]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0192779","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,15]]}}}